- Home
- PTGX vs PLXS Comparison
PTGX vs PLXS Comparison
Compare PTGX & PLXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTGX | PLXS |
|---|---|---|
| Founded | 2006 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electrical Products |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.0B |
| IPO Year | 2016 | 1986 |
Fundamental Metrics
Financial Performance| Metric | PTGX | PLXS |
|---|---|---|
| Price | $89.29 | $149.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 4 |
| Target Price | $86.44 | ★ $157.50 |
| AVG Volume (30 Days) | ★ 898.7K | 164.5K |
| Earning Date | 11-06-2025 | 01-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.11 |
| EPS | 0.72 | ★ 6.26 |
| Revenue | $209,217,000.00 | ★ $4,032,966,000.00 |
| Revenue This Year | N/A | $10.99 |
| Revenue Next Year | $296.47 | $7.02 |
| P/E Ratio | $124.48 | ★ $24.02 |
| Revenue Growth | N/A | ★ 1.82 |
| 52 Week Low | $33.70 | $103.43 |
| 52 Week High | $93.25 | $172.89 |
Technical Indicators
Market Signals| Indicator | PTGX | PLXS |
|---|---|---|
| Relative Strength Index (RSI) | 64.67 | 60.30 |
| Support Level | $83.52 | $141.26 |
| Resistance Level | $90.85 | $151.86 |
| Average True Range (ATR) | 2.63 | 5.09 |
| MACD | -0.33 | 1.22 |
| Stochastic Oscillator | 83.62 | 88.05 |
Price Performance
Historical ComparisonAbout PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About PLXS Plexus Corp.
Plexus Corp designs, manufactures, and services complex products in demanding regulatory environments, supporting life-saving medical devices, mission-critical aerospace and defense products, industrial automation systems, and semiconductor capital equipment. Its integrated lifecycle solutions span design and development, supply chain solutions, new product introduction, manufacturing, and sustaining services for market and disruptive companies in the Aerospace/Defense, Healthcare/Life Sciences, and Industrial sectors. The Company operates through three reportable segments: AMER, APAC, and EMEA, with the majority of revenue from the APAC segment.